| __timestamp | Axsome Therapeutics, Inc. | BioMarin Pharmaceutical Inc. |
|---|---|---|
| Wednesday, January 1, 2014 | 4279200 | 461543000 |
| Thursday, January 1, 2015 | 6776987 | 634806000 |
| Friday, January 1, 2016 | 21199860 | 661905000 |
| Sunday, January 1, 2017 | 19957616 | 610753000 |
| Monday, January 1, 2018 | 23495055 | 696328000 |
| Tuesday, January 1, 2019 | 53647067 | 715007000 |
| Wednesday, January 1, 2020 | 70244579 | 628116000 |
| Friday, January 1, 2021 | 58060725 | 628793000 |
| Saturday, January 1, 2022 | 57947447 | 649606000 |
| Sunday, January 1, 2023 | 97944000 | 746773000 |
| Monday, January 1, 2024 | 187077000 | 747184000 |
Igniting the spark of knowledge
In the competitive world of pharmaceuticals, innovation is key to staying ahead. BioMarin Pharmaceutical Inc. and Axsome Therapeutics, Inc. exemplify this drive, albeit at different scales. Over the past decade, BioMarin has consistently invested heavily in research and development, with their R&D spending peaking at approximately $747 million in 2023. This represents a steady increase of about 62% from 2014. In contrast, Axsome Therapeutics, while operating on a smaller scale, has shown a remarkable growth trajectory. Their R&D expenses surged by over 2,000% from 2014 to 2023, reaching nearly $98 million. This stark difference highlights BioMarin's established presence and Axsome's aggressive push to innovate and expand. As the pharmaceutical landscape evolves, these investments underscore the critical role of R&D in driving future breakthroughs and maintaining competitive advantage.
AstraZeneca PLC vs Axsome Therapeutics, Inc.: Strategic Focus on R&D Spending
Research and Development Expenses Breakdown: Novartis AG vs BioMarin Pharmaceutical Inc.
R&D Insights: How Bristol-Myers Squibb Company and BioMarin Pharmaceutical Inc. Allocate Funds
Comparing Innovation Spending: Zoetis Inc. and BioMarin Pharmaceutical Inc.
Who Prioritizes Innovation? R&D Spending Compared for Regeneron Pharmaceuticals, Inc. and BioMarin Pharmaceutical Inc.
Comparing Innovation Spending: Alnylam Pharmaceuticals, Inc. and Axsome Therapeutics, Inc.
Who Prioritizes Innovation? R&D Spending Compared for Neurocrine Biosciences, Inc. and Axsome Therapeutics, Inc.
Research and Development: Comparing Key Metrics for Incyte Corporation and Axsome Therapeutics, Inc.
BioMarin Pharmaceutical Inc. or Pharming Group N.V.: Who Invests More in Innovation?
Who Prioritizes Innovation? R&D Spending Compared for BioMarin Pharmaceutical Inc. and Amphastar Pharmaceuticals, Inc.
Analyzing R&D Budgets: BioMarin Pharmaceutical Inc. vs Viridian Therapeutics, Inc.
Research and Development Expenses Breakdown: Axsome Therapeutics, Inc. vs Geron Corporation